Cann Group (ASX:CAN) Tariff Resilience Score: 5/10 (As of Jun. 27, 2026)


What is Cann Group Tariff Resilience Score?

Cann Group ASX:CAN Tariff Resilience Score is 5 as of Jun. 27, 2026. The stock has 7 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Cann Group ranks better than 84.58% on this metric.

Cann Group has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Cann Group has Cann Group faces moderate tariff exposure due to its reliance on imported agricultural equipment. The company is exploring local suppliers and has some pricing power. Previous tariffs have impacted costs, but industry-specific exemptions provide some relief.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Cann Group might have Average Resilient.

Cann Group  (ASX:CAN) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Cann Group Tariff Resilience Score Related Terms

ASX:CAN vs ZTS: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cann Group's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cann Group Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cann Group's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Cann Group's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 5 mean?
Cann Group (ASX:CAN) has a Tariff Resilience Score of 5 as of Jun. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Cann Group ranks #159 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 15.4%.
Is Cann Group's Tariff Resilience Score too high?
Cann Group's current Tariff Resilience Score is 5. Based on the distribution chart, Cann Group ranks #159 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Cann Group's Tariff Resilience Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cann Group ranks #159 out of 1031 companies for Tariff Resilience Score. This places Cann Group in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Cann Group's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cann Group stock overvalued right now?
Based on GuruFocus' analysis, Cann Group (ASX:CAN) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 85% below its estimated fair value. The current Tariff Resilience Score is 5. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Cann Group (ASX:CAN), the current Tariff Resilience Score is 5 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cann Group Business Description

Other Exchanges CNGGF:USA
Address 262-276 Lorimer Street, Ground Floor, Port Melbourne, VIC, AUS, 3207
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.